SITC seeks nominations for the Steven A. Rosenberg Scholars Award

MD Anderson, AmMax Bio announce agreements to develop immunotherapy for MRD-positive cancers

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Researchers design immunotherapy for glioblastoma

David B. Weiner, of the Wistar Institute, and his laboratory, created a new therapeutic design for glioblastoma, the deadliest form of brain cancer.

December 06, 2024

Vol.50 No.45

Clinical Roundup

UVA Health tests focused ultrasound to increase immune response in melanoma

A research team at UVA Health is testing the ability of focused ultrasound to increase the immune response to immunotherapy in melanoma. UVA’s work with focused ultrasound already has led to life-changing new treatments for Parkinson’s disease and essential tremor and pushed the technology to the forefront of medical research.

November 22, 2024

Vol.50 No.44

In Brief

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

November 15, 2024

Vol.50 No.43

Clinical Roundup

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Researchers from the USC Norris Comprehensive Cancer Center found evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases. The study has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal cancer.

November 15, 2024

Vol.50 No.43

SITC seeks nominations for the Steven A. Rosenberg Scholars Award

YOU MAY BE INTERESTED IN

MD Anderson, AmMax Bio announce agreements to develop immunotherapy for MRD-positive cancers

Researchers design immunotherapy for glioblastoma

UVA Health tests focused ultrasound to increase immune response in melanoma

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Renew today!

Subscriber content

Never miss an issue!

Login